Jennie Orr Appointed Chief Strategy and Business Officer at Camargo Pharmaceutical Services, LLC

CINCINNATI, Oct. 13, 2020 /PRNewswire/ — Camargo Pharmaceutical Services, LLC, a global drug development and commercial partner, announced today the appointment of Jennie Orr as Chief Strategy and Business Officer. In this newly created senior leadership role, Orr will lead the development, communication and execution of corporate strategic growth initiatives including both organic growth and its mergers and acquisitions activities.

“Jennie has consistently demonstrated her strong leadership abilities and her dedication to Camargo’s values since she joined us in 2018,” Camargo CEO Dan Duffy said. “Having her in this position will enable us to advance our operational vision and achieve our growth expectations for the future.”

Camargo is a leading global strategy, regulatory and commercial partner for emerging and mid-size biopharma companies and has been instrumental in helping numerous pharmaceutical companies identify opportunities, develop products and obtain FDA approvals. Its work in orphan drugs, improved drugs, oncology and many

Read More

Erie economic development chief has a ‘passion’ for community service

Kevin Flowers
 
| Erie Times-News
play

Debra Smith never thought about making history.

When Smith began working for the city of Erie as an employment and training accountant in December 1985, the Erie native and Indiana University of Pennsylvania graduate was happy to have found a steady job working with numbers.

She figured that her time with city government would eventually lead to a career as a certified public accountant. 

Later, she began crunching the numbers for a number of city economic and community development initiatives, and that’s when things changed. 

Smith started to comprehend the humanity represented in those ledgers, reports and spreadsheets — and realized she wanted to do even more. 

“I was dealing with Community

Read More

A chief investment strategist explains why making short-term bets ahead of the election is a risky strategy



a man talking on a cell phone: Johannes Eisele/Getty Images


© Johannes Eisele/Getty Images
Johannes Eisele/Getty Images

  • A Charles Schwab chief investment strategist explained why making short-term bets ahead of the election is a risky strategy.
  • In the span of the last 30 election cycles, there have been a range of significant impacts on market performance that had “little-to-no relationship” with the incumbent party in the White House, the strategist, Liz Ann Sonders, noted.
  • Considering the multitude of market outcomes in every election cycle, she said “the economy impacts elections more than elections impact the economy.”
  • Investors looking for clear connections between the election and market performance cannot expect easy answers, she said.
  • Visit Business Insider’s homepage for more stories.

Betting on election outcomes is risky as history makes it clear that the relationship between politics and the stock market is varied and absent of consistency, according to a chief investment strategist at Charles Schwab, Liz Ann Sonders.

Loading...

Load Error

Read More

Wall Street strategy chief says the market is flashing bullish signals as more stocks start to rally


  • Miller Tabak’s chief market strategist told CNBC on Friday the stock market is signaling it has upside potential before Election Day. 
  • Matt Maley cited the outperformance of the Russell 2000 index and said small-cap stocks and chip stocks have room to grow. 
  • He’s less optimistic about the market in the long term, however. A second wave of the coronavirus and an expensive market could be bearish after the election, he said. 

Matt Maley of Miller Tabak  told CNBC on Friday that the stock market is signaling it has upside potential before Election Day.

The chief market strategist said he is watching the recent outperformance of small-cap stocks. As of Thursday, the Russell 2000 small-cap index was up almost 6% week-to-date, compared to a roughly 3% gain in the S&P 500. The broadening out of the stock market rally, which was previously dominated by mega-cap tech names, is

Read More

A Wall Street strategy chief says the market is flashing bullish signals as more stocks start to rally



a man wearing a suit and tie: CNBC TV


© CNBC TV
CNBC TV

  • Miller Tabak’s chief market strategist told CNBC on Friday the stock market is signaling it has upside potential before Election Day. 
  • Matt Maley cited the outperformance of the Russell 2000 index and said small-cap stocks and chip stocks have room to grow. 
  • He’s less optimistic about the market in the long term, however. A second wave of the coronavirus and an expensive market could be bearish after the election, he said. 

Matt Maley of Miller Tabak  told CNBC on Friday that the stock market is signaling it has upside potential before Election Day.

Loading...

Load Error

The chief market strategist said he is watching the recent outperformance of small-cap stocks. As of Thursday, the Russell 2000 small-cap index was up almost 6% week-to-date, compared to a roughly 3% gain in the S&P 500. The broadening out of the stock market rally, which was previously dominated by

Read More

Ludovic Blanquet Joins smartTrade as Chief Product and Strategic Planning Officer

LONDON & AIX-EN-PROVENCE, France–(BUSINESS WIRE)–smartTrade Technologies today announces that Ludovic Blanquet has joined as Chief Product and Strategic Planning Officer. Ludovic will support smartTrade to deliver world class integrated eTrading solutions.

Ludovic brings 20 years of industry experience to the role. He joins from Finastra where he was the Global Head of Product Strategy across its five lines of business. Prior to this, he built Credit Agricole APAC’s global equities trading platform and was APAC regional director for SmartStream, a corporate banking software vendor. Ludovic has experience working across multiple international markets having lived in Tokyo, London and Singapore during his career.

Ludovic will help shape smartTrade’s vision to deliver the leading cross-asset eTrading solution, capitalising on its market leading eFX LiquidityFX (LFX) cloud offering. Now based in London, Ludovic will lead a team of strategy and product managers responsible for designing and delivering on the future product

Read More

Hyde Engineering + Consulting Announces Appointment of Chief Operating Officer

BOULDER, Colo., Oct. 7, 2020 /PRNewswire/ — Hyde Engineering + Consulting, Inc. (Hyde) a worldwide partner for solution-based pharmaceutical design and consultant services, announced the appointment of Kalpesh Patel as Chief Operating Officer (COO).  Patel will lead Hyde’s growing global enterprise, translating the growth strategies set by Hyde’s Board of Directors and CEO to maximize profitability.

“I’m embracing this role with the focused calm and practical ideology that led me here. As I accept this new challenge, I will be relying on my extremely capable colleagues to work towards Hyde’s global integration, focusing on the consistency of operational processes and efficient utilization of our combined talents. I’m sincerely honored to be selected into this role and will put forth my best efforts to maintain company culture and sustainability, expanding that to Hyde’s global entity,” Kalpesh Patel, COO.

“From first joining the company in 2005, Kalpesh has been and

Read More

Caris Life Sciences Appoints Brian Lamon, Ph.D., as Chief Business Officer, Head of BioPharma Business Development

Lamon to oversee business development strategy and execution, and brings over 15 years of pharmaceutical and academia experience to the company

IRVING, Texas, Oct. 6, 2020 /PRNewswire/ — Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, announced today that Brian Lamon, Ph.D., has been appointed Chief Business Officer, Head of BioPharma Business Development.

Caris Life Sciences Logo (PRNewsfoto/Caris Life Sciences)
Caris Life Sciences Logo (PRNewsfoto/Caris Life Sciences)

In this role, Lamon will be responsible for developing the partnering and business development strategy for the company and translating that strategy into actionable and achievable goals for the broader Caris organization.

“We are very excited to welcome Brian to Caris,” said Brian J. Brille, Vice Chairman of Caris Life Sciences. “His expertise in oncology clinical development, business development, translational medicine and medical affairs, and track record of maximizing value from external relationships will further advance

Read More